Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656329 | 0.81 | ALDH1A1 (0.54) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2607864 | 0.79 | — | — | |
| SCHEMBL2174701 | 0.78 | GAA (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12914686 | 0.78 | ALDH1A1 (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8607188 | 0.78 | ALDH1A1 (0.62) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL3037432 | 0.77 | MGAM (0.48) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2174959 | 0.76 | TSHR (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL129132 | 0.76 | MGAM (0.52) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL10001051 | 0.75 | MGAM (0.67) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL3342301 | 0.75 | MGAM (0.46) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1496883-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA-KETOALKANOIC ACID, ESTER OR AMIDE | Critical Therapeutics, Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030216470-A1 | Method for treating ileus | CRITICAL THERAPEUTICS, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003088956-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA -KETOALKANOIC ACID OR - ESTER OR - AMIDE | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-2493467-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS | HILLS PET NUTRITION INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2519115-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILLS PET NUTRITION INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9173422-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-1874407-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9011900-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8999375-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2005002563-A2 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040068006-A1 | Method for preventing acute renal failure | CRITICAL THERAPEUTICS, INC. (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030216470-A1 | Method for treating ileus | CRITICAL THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003088956-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA -KETOALKANOIC ACID OR - ESTER OR - AMIDE | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | MGAM 347/4885GAA 82/4885SI 49/4885 |
| US-20040068006-A1 | Method for preventing acute renal failure | ELOVL6, ELOVL3, LIPA | MGAM 354/4885GAA 1303/4885SI 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.